Abstract
Objectives: After approval of elexacaftor/tezacaftor/ivacaftor (ETI) + ivacaftor (I) in Europe in August 2020, many people with CF (pwCF) experienced a significant improvement in several biomarkers such as pulmonary function test. Here we wanted to evaluate the impact of ETI+I on pulmonary exacerbations over a longer term in German people with CF.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Paper Title
Journal
Date
